Inhibrx Biosciences, Inc. (INBX)
(Delayed Data from NSDQ)
$14.23 USD
-0.34 (-2.33%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $14.23 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.23 USD
-0.34 (-2.33%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $14.23 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -61.68% and 1,534%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 11.36% and 1.49%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Pharma Stock Roundup: JNJ Reports Q4 Earnings, SNY Inks M&A Deal With INBX
by Kinjel Shah
J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sanofi (SNY) is set to acquire Inhibrx's (INBX) rare disease pipeline candidate, INBRX-101.
Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More
by Zacks Equity Research
Gilead Sciences (GILD) and Inhibrx (INBX) are in the spotlight on regulatory and pipeline updates.
Inhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Inhibrx, Inc. (INBX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi
by Zacks Equity Research
Sanofi (SNY) will acquire Inhibrx (INBX) for nearly $2.2 billion. Post-acquisition, it will retain the rare disease drug and spin out all other pipeline programs into a newly-traded public company.
Inhibrx, Inc. (INBX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -33.33% and 94.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Inhibrx, Inc. (INBX): Can Its 9.9% Jump Turn into More Strength?
by Zacks Equity Research
Inhibrx, Inc. (INBX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Inhibrx, Inc. (INBX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -18.75% and 8.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Inhibrx (INBX) Down on Updated Data From Bone Cancer Study
by Zacks Equity Research
Inhibrx (INBX) shares fall after it reports safety and efficacy data from phase I cohorts of a study evaluating its lead candidate INBRX-109 for chondrosarcoma.
Inhibrx, Inc. (INBX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of 10.89% and 60.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Amgen (AMGN) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of 6.09% and 1.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Inhibrx, Inc. (INBX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -15.48% and 21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Guardant Health (GH) delivered earnings and revenue surprises of -80% and 4.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Inhibrx, Inc. (INBX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -29.03% and 7.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of 7.14% and 69.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
KaloBios Pharmaceuticals Inc. (HGEN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
KaloBios Pharmaceuticals Inc. (HGEN) delivered earnings and revenue surprises of 34.69% and 0.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Inhibrx, Inc. (INBX) Soars 15%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Inhibrx, Inc. (INBX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Here's What Could Help Inhibrx, Inc. (INBX) Maintain Its Recent Price Strength
by Zacks Equity Research
Inhibrx, Inc. (INBX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Takeda (TAK) CMV Infection Drug Livtencity Gets FDA Approval
by Zacks Equity Research
The FDA grants approval to the new drug application seeking approval for Takeda's (TAK) maribavir for treating post-transplant cytomegalovirus infection.
Amryt (AMYT) Skin Disorder NDA Review Gets 3 Months Extension
by Zacks Equity Research
Amryt (AMYT) is seeking approval for Oleogel-S10 for treating epidermolysis bullosa, a rare genetic skin disorder, in the United States and Europe. The FDA extends the review period for the drug's NDA to reviewnew data submission.
Wall Street Analysts Predict a 32% Upside in Inhibrx, Inc. (INBX): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Inhibrx, Inc. (INBX) points to a 32% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Inhibrx, Inc. (INBX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of 5.26% and 153.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Inhibrx, Inc. (INBX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Inhibrx, Inc. (INBX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.